Pfizer acquisition of GlaxoSmithKline’s vaccines Nimenrix and Mencevax
October 2, 2015Pfizer Inc. has announced that it has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
“The addition of Nimenrix and Mencevax helps us to fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide,” said Susan Silbermann, president and general manager, Pfizer Vaccines.
“These vaccines add high-quality and complementary vaccines to our existing portfolio, allowing us to reach a broader global population.”
Pfizer About Nimenrix and Mencevax
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) is a single-dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. It is indicated for all age groups above one year of age. Launched three years ago, Nimenrix is currently registered and approved for sale in 63 countries across the European Economic Area (EEA 30), Canada, Australia and Emerging Markets, with registrations under review in another 17 countries across Africa, Asia, Eastern Europe and the Middle East.
Mencevax (meningococcal polysaccharide serogroups A, C, Y and W-135 vaccine) is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers in countries where the disease is endemic or highly epidemic. Mencevax is indicated for use across all age groups from 2 years of age, and is currently registered and approved in 78 countries across Africa, Asia, Australia, Europe, Latin America, Middle East and New Zealand.